RATIONALE: Central CB1 cannabinoid receptors regulate anxiety-like and appetitive consummatory behaviors. Pharmacological antagonism/inverse-agonism of CB1 receptors increases anxiety and decreases appetitive behaviors; however, neither well-defined dose nor context dependence of these effects has been simultaneously assessed in one behavioral assay. OBJECTIVES: We sought to determine the context and dose dependence of the effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in a model that allowed for simultaneous detection of anxiety-like and consummatory-related behaviors. METHODS: We determined the effects of the CB1 receptor antagonist/inverse-agonist, rimonabant, in the novelty-induced hypophagia (NIH) assay in juvenile male ICR mice. RESULTS: Rimonabant dose-dependently decreased consumption of a palatable reward solution completely independent of contextual novelty. Grooming and scratching behavior was also increased by rimonabant in a context-independent manner. In contrast, rimonabant increased feeding latency, a measure of anxiety-like behaviors, only in a novel, mildly anxiogenic context. The effects of rimonabant were specific since no effects of rimonabant on despair-like behavior were observed in the tail suspension assay. Blockade of CB2 receptors had no effect on novelty-induced increases in feeding latency or palatable food consumption. CONCLUSIONS: Our findings indicate that CB1 receptor blockade decreases the hedonic value of palatable food irrespective of environmental novelty, whereas the anxiogenic-like effects are highly context-dependent. Blockade of CB2 receptors does not regulate either anxiety-like or consummatory behaviors in the NIH assay. These findings suggest that rimonabant modulates distinct and dissociable neural processes regulating anxiety and consummatory behavior to sculpt complex and context-dependent behavioral repertories.
RATIONALE: Central CB1cannabinoid receptors regulate anxiety-like and appetitive consummatory behaviors. Pharmacological antagonism/inverse-agonism of CB1 receptors increases anxiety and decreases appetitive behaviors; however, neither well-defined dose nor context dependence of these effects has been simultaneously assessed in one behavioral assay. OBJECTIVES: We sought to determine the context and dose dependence of the effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in a model that allowed for simultaneous detection of anxiety-like and consummatory-related behaviors. METHODS: We determined the effects of the CB1 receptor antagonist/inverse-agonist, rimonabant, in the novelty-induced hypophagia (NIH) assay in juvenile male ICR mice. RESULTS:Rimonabant dose-dependently decreased consumption of a palatable reward solution completely independent of contextual novelty. Grooming and scratching behavior was also increased by rimonabant in a context-independent manner. In contrast, rimonabant increased feeding latency, a measure of anxiety-like behaviors, only in a novel, mildly anxiogenic context. The effects of rimonabant were specific since no effects of rimonabant on despair-like behavior were observed in the tail suspension assay. Blockade of CB2 receptors had no effect on novelty-induced increases in feeding latency or palatable food consumption. CONCLUSIONS: Our findings indicate that CB1 receptor blockade decreases the hedonic value of palatable food irrespective of environmental novelty, whereas the anxiogenic-like effects are highly context-dependent. Blockade of CB2 receptors does not regulate either anxiety-like or consummatory behaviors in the NIH assay. These findings suggest that rimonabant modulates distinct and dissociable neural processes regulating anxiety and consummatory behavior to sculpt complex and context-dependent behavioral repertories.
Authors: Satish Kathuria; Silvana Gaetani; Darren Fegley; Fernando Valiño; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Giovanna La Rana; Antonio Calignano; Arcangela Giustino; Maria Tattoli; Maura Palmery; Vincenzo Cuomo; Daniele Piomelli Journal: Nat Med Date: 2002-12-02 Impact factor: 53.440
Authors: Jenny L Wiley; James J Burston; Darnica C Leggett; Olga O Alekseeva; Raj K Razdan; Anu Mahadevan; Billy R Martin Journal: Br J Pharmacol Date: 2005-06 Impact factor: 8.739
Authors: Samuel W Centanni; Bridget D Morris; Joseph R Luchsinger; Gaurav Bedse; Tracy L Fetterly; Sachin Patel; Danny G Winder Journal: Neuropsychopharmacology Date: 2018-11-02 Impact factor: 7.853
Authors: Anthony L Berger; Angela M Henricks; Janelle M Lugo; Hayden R Wright; Collin R Warrick; Martin A Sticht; Maria Morena; Itziar Bonilla; Sarah A Laredo; Rebecca M Craft; Loren H Parsons; Pedro R Grandes; Cecilia J Hillard; Matthew N Hill; Ryan J McLaughlin Journal: Biol Psychiatry Date: 2018-05-08 Impact factor: 13.382
Authors: Katherine M Holleran; Hadley H Wilson; Tracy L Fetterly; Rebecca J Bluett; Samuel W Centanni; Rachel A Gilfarb; Lauren E R Rocco; Sachin Patel; Danny G Winder Journal: Neuropsychopharmacology Date: 2016-01-11 Impact factor: 7.853
Authors: Brian C Shonesy; Rebecca J Bluett; Teniel S Ramikie; Rita Báldi; Daniel J Hermanson; Philip J Kingsley; Lawrence J Marnett; Danny G Winder; Roger J Colbran; Sachin Patel Journal: Cell Rep Date: 2014-11-26 Impact factor: 9.423
Authors: Joseph R Luchsinger; Tracy L Fetterly; Kellie M Williford; Gregory J Salimando; Marie A Doyle; Jose Maldonado; Richard B Simerly; Danny G Winder; Samuel W Centanni Journal: Nat Commun Date: 2021-06-11 Impact factor: 14.919